Sign In
Buy QTTB
$21.38
+10.17 (+90.72%)
At Close: Jul 13, 2026
Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts
04:01pm, Monday, 13'th Jul 2026
Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Monday, 13'th Jul 2026
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and
Why Q32 Bio investors should take profits in the stock after 81% rally
01:15pm, Monday, 13'th Jul 2026
Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial. The trial that evaluated its anti-IL-7R
Q32 Bio's Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Study
12:02pm, Monday, 13'th Jul 2026
Q32 Bio NASDAQ: QTTB reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata, a d
Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why
08:55am, Monday, 13'th Jul 2026
Q32 Bio Inc. (NASDAQ:QTTB) stock is trading higher on Monday after the clinical-stage biotechnology company shared positive 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial.
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
06:59am, Monday, 13'th Jul 2026
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis -- -- 40.0% of patients
-- Conference call to be held Monday, July 13 th at 8:00 a.m. E.T. -- WALTHAM, Mass.
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
09:18am, Thursday, 28'th May 2026
I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts. Company expects mid-2026 data from both Part B [36-week topline] and Part A OLE of it
Q32 Bio Announces $55 Million Private Placement Financing
08:00am, Wednesday, 27'th May 2026
WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
10:56am, Tuesday, 26'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 145.7% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the posit
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
10:56am, Friday, 08'th May 2026
The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
06:59am, Tuesday, 05'th May 2026
-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Comple
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
06:59am, Wednesday, 08'th Apr 2026
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
10:55am, Monday, 30'th Mar 2026
The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive
08:33am, Monday, 30'th Mar 2026
Q32 Bio is now largely a single-asset story centered on Bempikibart in alopecia areata, with mid-2026 topline data as the key catalyst. Management sold ADX-097 to Akebia, which brings milestone and ro
